Aggrastat Injection Pre-mixed (HCPCS code J3246) is a clear, non-preserved, sterile solution premixed in a vehicle made iso-osmotic with 0.9%
Dimensions (box size)
15 mL Bolus Vial
3.75 mg in 15 mL
2.6" H x 1.7" W x 1.6" D
100 mL Vial
5 mg in 100 mL
(50 mcg/mL) pre-mixed vial with bottle hanger pre-attached
4" H x 2.25" W x 2.25" D
250 mL Bag
12.5 mg in 250 mL
10.9" H x 6.8" W x 1.4" D
Aggrastat is available through normal distribution at your wholesaler. For immediate supply, Aggrastat is available as a drop shipment via Express Overnight Delivery. It is important to provide your wholesaler with updated demand forecasts for Aggrastat.
Download or request Aggrastat’s resources for your hospital.
IMPORTANT SAFETY INFORMATION
AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Known hypersensitivity to any component of AGGRASTAT.
History of thrombocytopenia with prior exposure to AGGRASTAT.
Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.
Warnings and Precautions:
AGGRASTAT can cause serious bleeding. Most bleeding associated with AGGRASTAT occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic of potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue AGGRASTAT.
Thrombocytopenia: discontinue AGGRASTAT and heparin.
Bleeding is the most commonly reported adverse reaction.